A Phase II Study of Reirradiation With NBTXR3 in Patients With Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma
Latest Information Update: 07 Dec 2022
Price :
$35 *
At a glance
- Drugs Hafnium oxide (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nanobiotix
- 01 Dec 2022 Planned End Date changed from 18 May 2025 to 21 Nov 2022.
- 01 Dec 2022 Planned primary completion date changed from 18 May 2025 to 21 Nov 2022.
- 01 Dec 2022 Status changed from active, no longer recruiting to withdrawn prior to enrolment.